



Resource impact template

Resource impact

Published: 11 December 2025

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for transthyretin amyloidosis with cardiomyopathy:

- [Acoramidis for treating transthyretin amyloidosis with cardiomyopathy](#) (2025) NICE technology appraisal guidance 1121
- [Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy](#) (2025) NICE technology appraisal guidance 1115
- [Tafamidis for treating transthyretin amyloidosis with cardiomyopathy](#) (2024) NICE technology appraisal guidance 984